Brief: Epigenomics: FY Revenue At EUR 6.2 Mln
24/03/2022 07:06
March 24 (Reuters) - EPIGENOMICS AG ECXn.DE :
* REPORTS FINANCIAL RESULTS FOR FISCAL YEAR 2021
* FY ADJUSTED EBITDA LOSS -1.8 MILLION EUR
* FY NET LOSS -2.4 MILLION EUR VERSUS -11.7 MILLION EUR LOSS
YEAR
AGO
* FY REVENUE 6.2 MILLION EUR VERSUS 800,000 EUR YEAR AGO
* FY EPS LOSS 0.22 EUR VERSUS 2.02 EUR LOSS YEAR AGO
* ESTIMATES ITS 2022 REVENUE BETWEEN EUR 0.3 MILLION AND EUR
0.8
MILLION.
* FOR 2022 EBITDA (BEFORE SHARE-BASED PAYMENT EXPENSES),
EPIGENOMICS FORECASTS A RANGE OF EUR -15.0 MILLION TO EUR -17.0
MILLION.
Source text for Eikon: ID:nEQ4mZYTqa
Further company coverage: ECXn.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns